ImmunoTherapyNews.net

Cancer immunotherapy

XagenaNewsletter
Xagena Mappa
Medical Meeting
Ematobase.it

Search results for "Nivolumab"

Patients with squamous non-small-cell lung cancer that is refractory to multiple treatments have poor outcomes. Researchers have assessed the activity of Nivolumab ( Opdivo ), a fully human IgG4 PD-1 ...


The anti-programmed death-1 ( PD-1 ) antibody Nivolumab ( Opdivo ) has clinical activity in patients with metastatic melanoma. Nivolumab plus vaccine was investigated as adjuvant therapy in resected ...


Nivolumab ( Opdivo ) is a fully human immunoglobulin G4 programmed death-1 immune checkpoint inhibitor antibody that restores T-cell immune activity. This phase II trial assessed the antitumor activ ...


Nivolumab ( Opdivo ) was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients with Ipilimumab-refractory metastatic melanoma. The use of Nivolum ...


Both Ipilimumab, an anti–cytotoxic T-lymphocyte–associated antigen 4 monoclonal antibody ( Yervoy ) and Nivolumab, an anti–programmed death 1 monoclonal antibody ( Opdivo ), have been approved by the ...


Programmed death-1 ( PD-1 ) is a co-inhibitory receptor expressed on activated T cells which regulates antitumor immunity. Nivolumab ( Opdivo ) is a fully-humanized IgG4 that blocks the engagement o ...


PD-1 antibody, Nivolumab ( Opdivo ), was administered with/without a multi-peptide vaccine to 126 patients ( pts ) with unresectable melanoma that failed at least one regimen and were Ipilimumab ( Yer ...


Nivolumab ( Opdivo ) is a programmed death-1 ( PD-1 ) immune checkpoint inhibitor which has shown durable tumor responses in multiple cancer types and prolongs overall survival in patients with melano ...


Strategies to help improve the efficacy of the immune system against cancer represent an important innovation, with recent attention having focused on anti-programmed death (PD)-1 / PD-ligand 1 (L1) m ...


Treatment with the immune checkpoint inhibitor Nivolumab ( Opdivo ) has yielded durable responses in some patients with advanced non-small cell lung cancer ( NSCLC ), with a five-year survival rate of ...